journal article·2020-11Open access

Nanoparticle-based “Two-pronged” approach to regress atherosclerosis by simultaneous modulation of cholesterol influx and efflux

Hongliang He, Jing Wang, Paul J. Yannie, William J. Korzun, Hu Yang, Shobha Ghosh

Biomaterials· Volume 260

Abstract

Reduction of lipoprotein uptake by macrophages and stimulation of cholesterol efflux are two essential steps required for atherosclerotic plaque regression. We used the optimized mannose-functionalized dendrimeric nanoparticle (mDNP)-based platform for macrophage-specific delivery of therapeutics to simultaneously deliver SR-A siRNA (to reduce LDL uptake) and LXR ligand (LXR-L, to stimulate cholesterol efflux) - a novel "Two-pronged" approach to facilitate plaque regression. mDNP-mediated delivery of SR-A siRNA led to a significant reduction in SR-A expression with a corresponding decrease in uptake of oxLDL. Delivery of LXR-L increased expression of ABCA1/G1 and cholesterol efflux. Combined delivery of siRNA and LXR-L led to a significantly greater decrease in macrophage cholesterol content compared to either treatment alone. Administration of this in vitro optimized formulation of mDNP complexed with SR-A-siRNA and LXR-L (Two-pronged complex) to atherosclerotic LDLR-/- mice fed western diet (TD88137) led to significant regression of atherosclerotic plaques with a corresponding decrease in aortic cholesterol content.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Cholesterol and Lipid Metabolism · Cancer, Lipids, and Metabolism · Peroxisome Proliferator-Activated Receptors

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (49)

Show source-provided references
1. Natural history of aortic and coronary atherosclerotic lesions in youth: findings from the PDAY study10.1161/01.ATV.13.9.1291 ↗
2. Natural history and risk factors for early human atherogenesis. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) research group10.1093/clinchem/41.1.134 ↗
3. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths10.1016/S0140-6736(07)61778-4 ↗
4. Major lipids, apolipoproteins, and risk of vascular disease10.1001/jama.2009.1619 ↗
5. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials10.1016/S0140-6736(10)61350-5 ↗
6. Evolocumab and clinical outcomes in patients with cardiovascular disease10.1056/NEJMoa1615664 ↗
7. Cholesterol removal from plaques and elimination from the body: change in paradigm to reduce risk for heart disease10.2217/clp.14.35 ↗
8. Cellular cholesterol flux studies: methodological considerations10.1016/S0021-9150(01)00713-4 ↗
9. Macrophage-specific transgenic expression of cholesteryl ester hydrolase significantly reduces atherosclerosis and lesion necrosis in Ldlr–/–mice10.1172/JCI30485 ↗
10. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice10.1172/JCI200112517 ↗
11. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXRα10.1073/pnas.200367697 ↗
12. Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines10.1021/jm0255116 ↗
13. T‐0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor‐deficient mice10.1016/S0014-5793(02)03578-0 ↗
14. Role of LXRs in control of lipogenesis10.1101/gad.850400 ↗
15. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles10.1074/jbc.M204887200 ↗
16. Development of mannose functionalized dendrimeric nanoparticles for targeted delivery to macrophages: use of this platform to modulate atherosclerosis10.1016/j.trsl.2017.10.008 ↗
17. Bolstering cholesteryl ester hydrolysis in liver: a hepatocyte-targeting gene delivery strategy for potential alleviation of atherosclerosis10.1016/j.biomaterials.2017.03.024 ↗
18. Stable overexpression of human macrophage cholesteryl ester hydrolase results in enhanced free cholesterol efflux from human THP1 macrophages10.1152/ajpcell.00306.2006 ↗
19. Macrophage-specific transgenic expression of cholesteryl ester hydrolase attenuates hepatic lipid accumulation and also improves glucose tolerance in ob/ob mice10.1152/ajpendo.00511.2011 ↗
20. A rapid method of total lipid extraction and purification10.1139/y59-099 ↗
21. The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease10.1016/j.pharmthera.2017.07.010 ↗
22. Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis10.1161/01.ATV.0000056743.42348.59 ↗
23. Synthetic high-density lipoprotein-mediated targeted delivery of liver X receptors agonist promotes atherosclerosis regression10.1016/j.ebiom.2017.12.021 ↗
24. Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis10.1002/adhm.201400337 ↗
25. Nanoparticle therapy for vascular diseases10.1161/ATVBAHA.118.311569 ↗
26. Emerging concepts in dendrimer‐based nanomedicine: from design principles to clinical applications10.1111/joim.12280 ↗
27. Dendrimers in biomedical applications—reflections on the field10.1016/j.addr.2012.09.030 ↗
28. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease10.1161/01.CIR.87.6.1781 ↗
29. Dyslipidemia and the vulnerable plaque10.1053/pcad.2002.123474 ↗
30. Mintz · J. Am. Coll. Cardiol. · 2001 · 37 · 147810.1016/S0735-1097(01)01175-5 ↗
31. The goal of achieving atherosclerotic plaque regression with lipid-lowering therapy: insights from IVUS trials10.5551/jat.48603 ↗
32. Lipid synthesis in macrophages during inflammation in vivo: effect of agonists of peroxisome proliferator activated receptors α and γ and of retinoid X receptors
33. Alternative macrophage activation and metabolism10.1146/annurev-pathol-011110-130138 ↗
34. Improved insulin sensitivity in high fat-and high cholesterol-fed Ldlr−/− mice with macrophage-specific transgenic expression of cholesteryl ester hydrolase role OF macrophage inflammation and infiltration into adipose tissue10.1074/jbc.M109.069781 ↗
35. Myricetin ameliorates atherosclerosis in the low-density-lipoprotein receptor knockout mice by suppression of cholesterol accumulation in macrophage foam cells10.1186/s12986-019-0354-7 ↗
36. Naoxintong retards atherosclerosis by inhibiting foam cell formation through activating PPARα pathway10.2174/1566524019666190207143207 ↗
37. Atherosclerotic lesion progression is attenuated by reconstitution with bone marrow from macrophage-specific cholesteryl ester hydrolase transgenic mice10.1152/ajpregu.00277.2011 ↗
38. Effect of macrophage overexpression of murine liver X receptor-α (LXR-α) on atherosclerosis in LDL-receptor deficient mice10.1161/ATVBAHA.108.175257 ↗
39. High-density lipoprotein-targeted therapy and apolipoprotein AI mimetic peptides10.1253/circj.CJ-15-0960 ↗
40. Acute ApoA-I Milano administration induces plaque regression and stabilisation in the long term10.1160/TH12-08-0556 ↗
41. CSL112 (apolipoprotein AI [human]) enhances cholesterol efflux similarly in healthy individuals and stable atherosclerotic disease patients10.1161/ATVBAHA.118.310538 ↗
42. Combined deletion of macrophage ABCA1 and ABCG1 leads to massive lipid accumulation in tissue macrophages and distinct atherosclerosis at relatively low plasma cholesterol levels10.1161/ATVBAHA.107.156935 ↗
43. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice
44. Rivaroxaban with or without aspirin in stable cardiovascular disease10.1056/NEJMoa1709118 ↗
45. Synergy of dual pathway inhibition in chronic cardiovascular disease: lessons from the COMPASS trial10.1161/CIRCRESAHA.118.313141 ↗
46. Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice10.1038/s41598-019-54224-9 ↗
47. Apolipoprotein AI) promotes atherosclerosis regression in diabetic mice by suppressing myelopoiesis and plaque inflammation10.1161/CIRCULATIONAHA.119.039476 ↗
48. LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression10.1172/JCI38911 ↗
49. Coronary atheroma regression and adverse cardiac events: a systematic review and meta-regression analysis10.1016/j.atherosclerosis.2019.03.005 ↗